IGF1 and neoplasm: These effects are strengthened by IGF1 overexpression and blunted by IGF1 knockdown or neutralization in CAFs, and are reduced by tumor-cell IGF1R loss but enhanced by IGF1R gain; PTPN9 overexpression partially counteracts CAF-CM–induced motility.